The aim of our study was to determine the factors influencing galectin-3 levels in patients with acute coronary syndrome and decreased left ventricular ejection fraction. We collected material from 37 successive patients with acute coronary syndrome and decreased left ventricular ejection fraction, of which 19 patients had atrial fibrillation, and 18 patients who were without atrial fibrillation constituted a control group. Blood samples used for the biochemical measurements were obtained on the third day from acute coronary syndrome. We used Statistical Package for Social Sciences for data analysis. A p-value less than 0.05 was considered to be a measure of statistical significance. Galectin-3 concentration is directly correlated with age and B-type natriuretic peptide level. Also, our results showed an inverse correlation between galectin-3 and total body weight, body mass index, body surface area and creatinine clearance. The following variables were found to be significant predictors of galectin-3 level: decreased left ventricular ejection fraction, total body weight, LDL concentration and body mass index. We identified factors that can predict a decrease in the left ventricular ejection fraction below 45% after acute coronary syndrome: atrial fibrillation increases the risk by almost six times, and urea concentration increases the risk by 1.2 times for each unit. Left ventricular ejection fraction below 45%, TBW, body mass index and LDL level are good predictors of galectin-3 concentration in patients with ACS and decreased left ventricular ejection fraction. Atrial fibrillation could be a predictive marker of decreased left ventricular ejection fraction.
1. Lok DJ, Lok SI, Bruggink-Andre de la Porte PW, et al. Galectin 3 is an independent marker for ventricular remodeling and mortality in patients with chronic hart failure. Clin Res Cardiol 2013;102:103-10 https://doi.org/10.1007/s00392-012-0500-y
3. Szadkowska I, Wlazeł RN, Migała M, et al. The association between galectin-3 and occurrence of reinfarction early after first myocardial infarction. Biomarkers. 2013;18:655-9. https://doi.org/10.3109/1354750X.2013.840801
7. Tian L, Chen K, Cao J, et al. Galectin-3-induced oxidized low-density lipoprotein promotes the phenotypic transformation of vascular smooth muscle cells. MolMed Reps. 2015: 12; 4995-5002 https://doi.org/10.3892/mmr.2015.4075
8. Van der Velde, Lexis CP, Meijers WC, et al. Galectin-3 and sST2 in prediction of left ventricular ejection fraction after myocardial infarction. Clin Chim Acta. 2016;452:50-7 https://doi.org/10.1016/j.cca.2015.10.034
9. Grandin EW, Jarolim P, Murphy SA, et al. Galectin-3 and the Development of Heart failure after Acute Coronary Syndrome: Pilot Experience from PROVE IT-TIMI 22. Clin. Chem 2012;58:267-73 https://doi.org/10.1373/clinchem.2011.174359
10. Zou R, Kneller J, Leon LJ, Nattel S. Substrate size as a determinant of fibrillatory activity maintenance in a mathematical model of canine atrium. Am J Physiol Heart Circ Physiol 2005;289:H1002–H1012 https://doi.org/10.1152/ajpheart.00252.2005